MedTrace Logo

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Ezerosu Tab

NCT06225635 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-01-26

No results posted yet for this study

Summary

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Ezerosu Tab

Conditions

  • Hyperlipidemias

Interventions

DRUG

Ezerosu(monolayer tablet)

Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)

DRUG

Ezerosu(double layer tablet)

Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)

Sponsors & Collaborators

  • Shin Poong Pharmaceutical Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2022-03-07
Completion
2022-03-07

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06225635 on ClinicalTrials.gov